<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203108</url>
  </required_header>
  <id_info>
    <org_study_id>ATG in HLA-matched HSCT-2019</org_study_id>
    <nct_id>NCT04203108</nct_id>
  </id_info>
  <brief_title>ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis</brief_title>
  <official_title>ATG Used in Allogeneic Hematopoietic Stem Cell Transplantation From HLA-matched Sibling Donor as GVHD Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocols including ciclosporin A （CsA）+methotrexate (MTX) +mycophenolate Mofetil(MMF)
      have been widely used for graft-versus-host disease (GVHD) prophylaxis in allogeneic
      hematopoietic stem cell transplantation from HLA-matched sibling donor (MSD). Nevertheless,
      severe chronic graft-versus-host disease (cGVHD) remains an obstacle for MSD HSCT. A growing
      body of studies have suggested antithymocyte globulin (ATG) could reduce the incidence of
      cGVHD. This study is aim to evaluate the efficacy of a protocol that includes CsA, MTX, MMF
      and ATG in recipients of MSD HSCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of cGVHD</measure>
    <time_frame>2 year posttransplantation</time_frame>
    <description>cGVHD was graded as limited or extensive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 year posttransplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>2 year posttransplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of aGVHD</measure>
    <time_frame>100 days 1 year posttransplantation</time_frame>
    <description>aGVHD was defined according to the 1994 Consensus Conference on Acute GVHD Grading and graded from I to IV.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">266</enrollment>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>ATG group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG group refers to treatment with a protocol including low-dose ATG, CsA, short-term MTX and MMF as GVHD prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-ATG group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-ATG group refers to treatment with a protocol including CsA, short-term MTX and MMF as GVHD prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>In ATG group, ATG will be intravenously infused via a central venous catheter in day -1 at a dose of 2.5mg/kg.</description>
    <arm_group_label>ATG group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CsA</intervention_name>
    <description>In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.</description>
    <arm_group_label>ATG group</arm_group_label>
    <arm_group_label>non-ATG group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).</description>
    <arm_group_label>ATG group</arm_group_label>
    <arm_group_label>non-ATG group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMF</intervention_name>
    <description>In both groups, MMF will be administrated at a dose of 1.0g/d.</description>
    <arm_group_label>ATG group</arm_group_label>
    <arm_group_label>non-ATG group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A patient age of 18-65 years

          2. MSD transplant recipient

          3. Subjects (or their legally acceptable representatives) must have signed an informed
             consent document indicating that they understand the purpose of and procedures
             required for the study and are willing to participate in the study

        Exclusion Criteria:

          1. Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood
             pressure)

          2. Patients with any conditions not suitable for the trial (investigators' decision)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifa Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ren Lin, MD</last_name>
    <phone>+86-020-62787883</phone>
    <email>lansinglinren@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ren Lin</last_name>
      <phone>+86-020-62787883</phone>
      <email>lansinglinren@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>antithymocyte globulin</keyword>
  <keyword>graft-versus-host disease</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

